A phase II study of thalidomide in patients with brain metastases from malignant melanoma

Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Introduction. Brain metastases develop in nearly half of the patients with advanced melanoma and in 15 to 20% of these patients CNS is the first site of relapse. Overall median survival is short, ranging from 2 to 4 months. Thalidomide has antiangiogenic and immunomodulatory effects. Results obtained in prior trials indicate that Thalidomide acts as a cytostatic agent in metastatic melanoma. We evaluated single agent antitumour activity and toxicity of Thalidomide in a phase II setting in patients with brain metastases associated with metastatic melanoma. Material and methods. Patients with measurable metastatic melanoma in progression and with PS
JournalActa Oncologica
Pages (from-to)1-5
Number of pages4
Publication statusPublished - 6 Feb 2008